© 2021 MJH Life Sciences and HCPLive - Clinical news for connected physicians. All rights reserved.
© 2021 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
April 25, 2021
The Phase 2b study shows a higher proportion of ligelizumab-treated patients achieved complete response or lower severity score compared with omalizumab.
April 12, 2021
The approval of the sBLA means greater flexibility and reduced barriers in care during the pandemic.
December 22, 2020
The 5 companies issued letters will have 15 days to submit a compliance plan.
December 16, 2020
The FDA approvals of biologics for atopic dermatitis and psoriasis have ushered in a new era for the once-stagnant field of pediatric dermatology.
December 15, 2020
Approval allows Almirall to move forward with the topical ointment for individuals with AK on the face or scalp.
December 10, 2020
In new phase 3b findings, a greater proportion of patients treated with upadacitinib achieved EASI 75 at week 16 than those who received dupilumab.
December 03, 2020
There is a gap between the efficacy of biologics in trials and the real-world setting.
December 01, 2020
Strict avoidance of systemic corticosteroids among patients with psoriasis may be unnecessary.
November 30, 2020
Largest study of multiple health indicators over time finds widening disparities in health by race, despite increased targeted funding.
November 28, 2020
The risk of suicidality and psychological adverse events appears to be particularly high in younger men with alopecia who are given finasteride.